US 12,377,079 B2
Antibacterial compounds and uses thereof
Paula I. Watnick, Boston, MA (US); and Julie Szu Yu, Boston, MA (US)
Assigned to The Children's Medical Center Corporation
Appl. No. 17/311,433
Filed by The Children's Medical Center Corporation, Boston, MA (US)
PCT Filed Dec. 5, 2019, PCT No. PCT/US2019/064652
§ 371(c)(1), (2) Date Jun. 7, 2021,
PCT Pub. No. WO2020/118036, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/776,134, filed on Dec. 6, 2018.
Prior Publication US 2022/0023270 A1, Jan. 27, 2022
Int. Cl. A61K 31/433 (2006.01); A61K 31/165 (2006.01); A61K 31/341 (2006.01); A61K 31/357 (2006.01); A61K 31/4525 (2006.01); A61K 31/519 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/433 (2013.01) [A61K 31/165 (2013.01); A61K 31/341 (2013.01); A61K 31/357 (2013.01); A61K 31/4525 (2013.01); A61K 31/519 (2013.01); A61P 31/04 (2018.01)] 4 Claims
 
1. A pharmaceutical composition for the treatment of an antibiotic-resistant bacterial infection, the composition comprising a therapeutically effective amount of a compound of Formula II or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier;

OG Complex Work Unit Chemistry
wherein:
R8, R9, R10, R11, and R12 independently are H, alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclyl, acyl, allyl, OH, alkoxy, cyano, carboxy, CF3, halide, NH (alkyl), NH (aryl) or NH2; R13 and R14 are independently H, alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclyl, acyl, or allyl;
wherein any alkyl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl or aryl is optionally substituted with 1, 2, or 3 groups selected from OH, CN, SH, SO2NH2, SO2 (C1-C4) alkyl, SO2NH(C1-C4) alkyl, halogen, NH2, NH(C1-C4) alkyl, N[(C1-C4) alkyl]2, C(O)NH2, COOH, COOMe, acetyl, (C1-C8) alkyl, O(C1-C8) alkyl, O(C1-C5) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, haloalkyl, thioalkyl, cyanomethylene, alkylaminyl, aryl, heteroaryl, substituted aryl, NH2—C(O)-alkylene, NH (Me)-C(O)-alkylene, CH2—C(O)-lower alkyl, C(O)-lower alkyl, alkylcarbonylaminyl, CH2—[CH(OH)]m—(CH2)p—OH, CH2—[CH(OH)]m—(CH2)p—NH2 or CH2-aryl-alkoxy; or wherein any alkyl, cycloalkyl or heterocyclyl is optionally substituted with oxo;
“m” and “p” are independently 1, 2, 3, 4, 5 or 6, and
a therapeutically effective amount of an efflux pump inhibitor.